Determinants of Complementary Therapy Use among Registered Nurses in an Acute Care Setting.

INTRODUCTION: Alternatives are needed to traditional care to help patients manage pain and discomfort in acute care settings. Complementary and integrative therapies (CITs) involve alternative medicine practices that are assimilated into conventional care. The degree to which registered nurses (RNs) use CIT in acute care settings, however, remains unclear. This study identified determinants of CIT use among RNs in a US hospital. METHODS: A cross-sectional online survey was conducted. Nurse managers emailed invitations to study-eligible RNs, and the survey captured recent CIT use, as well as sociodemographic and training/experience exposures. Participants were employees in a western Wisconsin hospital. All participants were RNs at the target hospital and worked in acute care. CIT use was assessed with a single item that asked respondents to indicate which of 25 common CIT methods they have used or offered to patients. RESULTS: There were 164 respondents from 463 invited RNs (35% response rate). In the past 6 months, 79% reported the use of CIT with their patients. The most common practices were relaxed breathing, music therapy, essential oils, massage, and aromatherapy. The final multivariable logistic regression model found that RNs with ≥14 years of clinical experience had 72% lower odds of CIT use relative to those with 0-2 years of experience (p = 0.023). In addition, RNs who were married had 76% lower odds of CIT use relative to those not married (p = 0.017). Other factors such as age, gender, specialized CIT education, or nursing degree type had limited influence on CIT use. CONCLUSION: The use of CIT was generally high in this sample of hospital RNs, particularly among those who were not married and who were trained more recently. Future research should examine RN-led CIT effectiveness on patient outcomes in clinical settings.

Longitudinal dynamics of farmer and livestock nasal and faecal microbiomes and resistomes.

Globally, half a billion people are employed in animal agriculture and are directly exposed to the associated microorganisms. However, the extent to which such exposures affect resident human microbiomes is unclear. Here we conducted a longitudinal profiling of the nasal and faecal microbiomes of 66 dairy farmers and 166 dairy cows over a year-long period. We compare farmer microbiomes to those of 60 age-, sex- and ZIP code-matched people with no occupational exposures to farm animals (non-farmers). We show that farming is associated with microbiomes containing livestock-associated microbes; this is most apparent in the nasal bacterial community, with farmers harbouring a richer and more diverse nasal community than non-farmers. Similarly, in the gut microbial communities, we identify more shared microbial lineages between cows and farmers from the same farms. Additionally, we find that shared microbes are associated with antibiotic resistance genes. Overall, our study demonstrates the interconnectedness of human and animal microbiomes.

Age and Aspirin Dosing in Secondary Prevention of Atherosclerotic Cardiovascular Disease.

BACKGROUND: In patients with atherosclerotic cardiovascular disease, increasing age is concurrently associated with higher risks of ischemic and bleeding events. The objectives are to determine the impact of aspirin dose on clinical outcomes according to age in atherosclerotic cardiovascular disease. METHODS AND RESULTS: In the ADAPTABLE (Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness) trial, patients with atherosclerotic cardiovascular disease were randomized to daily aspirin doses of 81 mg or 325 mg. The primary effectiveness end point was death from any cause, hospitalization for myocardial infarction, or hospitalization for stroke. The primary safety end point was hospitalization for bleeding requiring transfusion. A total of 15 076 participants were randomized to aspirin 81 mg (n=7540) or 325 mg (n=7536) daily (median follow-up: 26.2 months; interquartile range: 19.0-34.9 months). Median age was 67.6 years (interquartile range: 60.7-73.6 years). Among participants aged <65 years (n=5841 [38.7%]), a primary end point occurred in 226 (7.54%) in the 81 mg group, and in 191 (6.80%) in the 325 mg group (adjusted hazard ratio [HR], 1.23 [95% CI, 1.01-1.49]). Among participants aged ≥65 years (n=9235 [61.3%]), a primary end point occurred in 364 (7.12%) in the 81 mg group, and in 378 (7.96%) in the 325 mg group (adjusted HR, 0.95 [95% CI, 0.82-1.10]). The age-dose interaction was not significant (P=0.559). There was no significant interaction between age and the randomized aspirin dose for the secondary effectiveness and the primary safety bleeding end points (P>0.05 for all). CONCLUSIONS: Age does not modify the impact of aspirin dosing (81 mg or 325 mg daily) on clinical end points in secondary prevention of atherosclerotic cardiovascular disease.